Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 501–600 of 1,002
Mesenchymal Stromal Cells: A New Tool against Graft-versus-Host Disease?
Baron, F., & Storb, R. F. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.09.003 · Cited by 111
“In the latter case, eradication of malignancies depends not only on the high-dose chemo/radiotherapy given in the conditioning regimen, but also on donor T and natural killer (NK) cells present in the graft (GVTeffect) [2-7].”
BackgroundNorth, J. M., Bakhsh, I., Marden, C. M., Pittman, H., Addison, E., Navarrete, C., Anderson, R. W., & Lowdell, M. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.85 · Cited by 104
“(12), for example, found no protection from relapse in recipients of KIR-mismatched stem cell transplants when the leukemic cells lacked expression of LFA-1.”
BackgroundRaffaghello, L., Prigione, I., Bocca, P., Morandi, F., Camoriano, M., Gambini, C., Wang, X., Ferrone, S., & Pistoia, V. (2005) · Oncogene · doi:10.1038/sj.onc.1208594 · Cited by 104
Long-term outcome after haploidentical stem cell transplantation in children
Lang, P., Greil, J., Bader, P., Handgretinger, R., Klingebiel, T. E., Schumm, M., Schlegel, P.-G., Feuchtinger, T. F., Pfeiffer, M. M., Scheel-Walter, H. G., et al. (2004) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2004.08.017 · Cited by 104
Natural killer cell–dendritic cell crosstalk in the initiation of immune responses
Walzer, T., Dalod, M., Vivier, É., & Zitvogel, L. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.s49 · Cited by 104
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
Chang, Y., Luznik, L., Fuchs, E. J., & Huang, X. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0265-2 · Cited by 105
“[110] showed that alloreactive NK cells in a mouse model provided the following benefits: (1) elimination of recipient acute myeloid leukemia (AML) cells; (2) destruction of recipient T cells, which permitted a conditioning regimen with reduced toxicity; and (3) ablation of recipient dendritic cells that trigger GVHD,…”
BackgroundMullally, A., & Ritz, J. (2006) · Blood · doi:10.1182/blood-2006-06-030858 · Cited by 126
EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS FOR CANCER IMMUNOTHERAPY
Cho, D., & Campana, D. (2009) · The Korean Journal of Laboratory Medicine · doi:10.3343/kjlm.2009.29.2.89 · Cited by 113
“tissues [51], suggesting the possibility of an NK-mediated graft-versus-leukemia (GVL) effect without systemic disease.”
BackgroundGraft-versus-host disease versus graft-versus-leukemia
Negrin, R. S. (2015) · Hematology · doi:10.1182/asheducation-2015.1.225 · Cited by 103
Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 120
NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential
Portale, F., & Mitri, D. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119521 · Cited by 123
“The concept of NK cells as a tool for cancer therapy was formally proved when the infusion of NK cells was first employed in the treatment of leukemia patients, with promising efficacy [38].”
Locatelli, F., Bauquet, A., Palumbo, G. A., Moretta, F., & Bertaina, A. (2013) · Immunology Letters · doi:10.1016/j.imlet.2013.09.027 · Cited by 101
Challenges and opportunities of allogeneic donor-derived CAR T cells
Yang, Y., Jacoby, E., & Fry, T. J. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000181 · Cited by 104
Solomon, S. R., Aubrey, M. T., Zhang, X., Piluso, A., Freed, B. M., Brown, S. L., Jackson, K. C., Morris, L. E., Holland, H. K., Solh, M., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.013 · Cited by 101
Shaw, B. E., Marsh, S. G. E., Mayor, N. P., Russell, N. H., & Madrigal, J. A. (2005) · Blood · doi:10.1182/blood-2005-08-3121 · Cited by 101
“Donor age, y, median (range) 35 (21-56) Recipient CMV serostatus, no.”
Loren, A. W., & Porter, D. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705898 · Cited by 101
Bellucci, R., Alyea, E. P., Chiaretti, S., Wu, C. J., Zorn, E., Weller, E. A., Wu, B., Canning, C. M., Schlossman, R. L., Munshi, N. C., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4463 · Cited by 101
Chaleff, S., Otto, M., Barfield, R. C., Leimig, T., Iyengar, R. V., Martin, J., Holiday, M., Houston, J., Geiger, T. L., Huppert, V., et al. (2007) · Cytotherapy · doi:10.1080/14653240701644000 · Cited by 101
Huenecke, S., Zimmermann, S. Y., Kloeß, S., Esser, R., Brinkmann, A., Tramsen, L., Koenig, M., Erben, S., Seidl, C., Tonn, T., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181bb46f7 · Cited by 111
Understanding of molecular mechanisms in natural killer cell therapy
Yoon, S. R., Kim, T., & Choi, I. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.114 · Cited by 118
Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells
Enqvist, M., Ask, E. H., Forslund, E., Carlsten, M., Abrahamsen, G., Béziat, V., Andersson, S., Schaffer, M., Spurkland, A., Bryceson, Y. T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401972 · Cited by 111
“tion (8, 36, 37), infectious diseases (38), autoimmunity, and disorders of pregnancy (1).”
BackgroundKröger, N. M., Binder, T. M., Zabelina, T., Wolschke, C., Schieder, H., Renges, H., Ayuk, F. A., Dahlke, J., EIERMANN, T. H., & Zander, A. R. (2006) · Transplantation · doi:10.1097/01.tp.0000235859.24513.43 · Cited by 100
“Haploidentical T-cell depleted stem cell transplantation for patients with acute myeloid leukemia resulted in a significant increase in overall survival and a reduced incidence of GvHD for those patients who were transplanted with KIR-ligand mismatch (1); however, the role of KIR-ligand mismatch in unrelated stem cell…”
BackgroundFoley, B. A., de Santis, D., van Beelen, E., Lathbury, L., Christiansen, F., & Witt, C. (2008) · Blood · doi:10.1182/blood-2008-01-132902 · Cited by 112
Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia
Bleakley, M., & Riddell, S. R. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2010.124 · Cited by 119
“After T-cell-depleted haploidentical HCT, donor NK cells can mediate a potent GVL effect against AML in the small subset of recipients who do not express donor class I human leukocyte antigen (HLA) molecules required to engage donor NK-inhibitory receptors”
BackgroundImmune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation
Chang, Y., Zhao, X., & Huang, X. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.028 · Cited by 100
Romagnani, C., Pietra, G., Falco, M., Millo, E., Mazzarino, P., Biassoni, R., Moretta, A., Moretta, L., & Mingari, M. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172369799 · Cited by 100
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
Frazao, A., Rethacker, L., Messaoudene, M., Avril, M., Toubert, A., Dulphy, N., & Caignard, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00661 · Cited by 107
Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer
Sivori, S., Chiesa, M. D., Carlomagno, S., Quatrini, L., Munari, E., Vacca, P., Tumino, N., Mariotti, F. R., Mingari, M. C., Pende, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02156 · Cited by 114
“This has been proven especially beneficial in acute myeloid leukemia (AML) adult patients (36), and in acute lymphoblastic leukemia (ALL) pediatric patients (37).”
BackgroundBlanc, K. L., Barrett, A. J., Schaffer, M., Hägglund, H., Ljungman, P. T., Ringdén, O. T. H., & Remberger, M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.05.015 · Cited by 99
“Our data may support studies treating patients with BM boost, mesenchymal stem cells, or evaluating the adoptive transfer of donor NK cells (which do not increase the risk of aGVHD) [29-31].”
ResultThe regulation of lymphocyte activation by inhibitory receptors
Leibson, P. J. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.03.006 · Cited by 110
Immunogenetics of killer cell immunoglobulin-like receptors
Parham, P. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.027 · Cited by 99
Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy
Luna, J. I., Grossenbacher, S. K., Murphy, W. J., & Canter, R. J. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1271874 · Cited by 100
“In addition, NK cells have been long known for their unique ability to reject allogeneic hematopoietic stem cells, and this observation has proved fruitful in studies on both graft-versusleukemia and graft-versus-host disease in the setting of bone marrow transplantation [80,81].”
BackgroundDavid, G., Djaoud, Z., Willem, C., Legrand, N., Rettman, P., Gagne, K., Cesbron, A., & Retière, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301580 · Cited by 98
Eguizabal, C., Zenarruzabeitia, O., Monge, J., Santos, S., Vesga, M. A., Maruri, N., Arrieta, A., Riñón, M., Tamayo-Orbegozo, E., Amo, L., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00439 · Cited by 99
Hauri-Hohl, M. M., Keller, M. P., Gill, J. W., Hafen, K., Pachlatko, E., Boulay, T., Peter, A., Holländer, G. A., & Krenger, W. (2007) · Blood · doi:10.1182/blood-2006-07-034157 · Cited by 98
Maki, G., Hayes, G. M., Naji, A., Tyler, T., Carosella, E. D., Rouas‐Freiss, N., & Gregory, S. A. (2008) · Leukemia · doi:10.1038/leu.2008.15 · Cited by 118
Carrington, M. N., & Norman, P. J. (2003) · Cited by 158
Circulating Tumor Cells: Diagnostic and Therapeutic Applications
Lin, E., Cao, T. M., Nagrath, S., & King, M. R. (2018) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-120947 · Cited by 102
Lamble, A. J., Kosaka, Y., Laderas, T., Maffit, A., Kaempf, A. J., Brady, L., Wang, W., Long, N., Saultz, J. N., Mori, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916206117 · Cited by 102
Umbilical Cord Mesenchymal Stem Cells Increase Expansion of Cord Blood Natural Killer Cells
Boissel, L., Tuncer, H. H., Betancur, M., Wolfberg, A., & Klingemann, H. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.06.016 · Cited by 97
Aggarwal, S., van de Loosdrecht, A. A., Alhan, C., Ossenkoppele, G. J., Westers, T. M., & Bontkes, H. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08683.x · Cited by 105
“T cell-depleted donor lymphocyte infusions (DLI) containing purified NK cells have also been used for the treatment of high-risk leukaemia and lymphomas (Kolb et al, 1990, 2004; Ruggeri et al, 2002 Soiffer et al, 2002; Passweg et al, 2004).”
MethodNi, Z., Knorr, D. A., Clouser, C. L., Hexum, M. K., Southern, P., Mansky, L. M., Park, I.-H., & Kaufman, D. S. (2011) · Journal of Virology · doi:10.1128/jvi.01774-10 · Cited by 97
“Cell-based immunotherapy using either T or NK effector cells has been used to treat malignancies such as leukemia, melanoma, and renal cell carcinoma (35, 39, 40).”
BackgroundManjappa, S., Bhamidipati, P. K., Stockerl-Goldstein, K. E., DiPersio, J. F., Uy, G. L., Westervelt, P., Liu, J., Schroeder, M. A., Vij, R., Abboud, C. N., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.10.003 · Cited by 97
“The NK cellemediated GVL effect in general seems to be restricted to patients with myeloid malignancies and could be the reason why this CMV reactivationerelated decreased relapse has been observed in patients with myeloid malignancies [6,7,28-30].”
BackgroundGodal, R., Bachanová, V., Gleason, M., McCullar, V., Yun, G. H., Cooley, S., Verneris, M. R., McGlave, P. B., & Miller, J. S. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.01.019 · Cited by 97
“Although NK cell alloreactivity has been reported for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) after KIR ligand– mismatched HCT [16-20], not all reports are in agreement with this [21-24], and the mechanism of apparent resistance in some studies is unclear.”
ResultCancer vaccines: progress reveals new complexities
Yu, Z., & Restifo, N. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16216 · Cited by 107
“Most surprisingly, clinical results from hematopoietic cell transplantation revealed that alloreactive NK cells in the donor graft prevented leukemia relapse in leukemic recipients (19).”
ResultUses and Growth of Hematopoietic Cell Transplantation
Horowitz, M. M. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch2 · Cited by 101
Adoptive cell therapy using engineered natural killer cells
Rezvani, K. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0601-6 · Cited by 106
Harnessing NK Cells for Cancer Treatment
Minetto, P., Guolo, F., Pesce, S., Greppi, M., Obino, V., Ferretti, E., Sivori, S., Genova, C., Lemoli, R. M., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02836 · Cited by 104
EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
Jing, R., Scarfò, I., Najia, M. A. T., da Rocha, E. L., Han, A., Sanborn, M., Bingham, T., Kubaczka, C., Jha, D. K., Falchetti, M., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.06.014 · Cited by 101
Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice
Asakura, S., Hashimoto, D., Takashima, S., Sugiyama, H., Maeda, Y., Akashi, K., Tanimoto, M., & Teshima, T. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39165 · Cited by 104
Relapse after Allogeneic Hematopoietic Cell Therapy
van den Brink, M. R. M., Porter, D. L., Giralt, S., Lu, S. X., Jenq, R. R., Hanash, A. M., & Bishop, M. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.10.023 · Cited by 97
“Despite this greater understanding we have not yet been able to translate these findings into significant improvements in outcomes except for a minority of patients (8).”
BackgroundBexte, T., Albinger, N., Al-Ajami, A., Wendel, P., Buchinger, L., Geßner, A., Alzubi, J., Särchen, V., Vogler, M., Rasheed, H. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52388-1 · Cited by 106
Zaia, J., Sun, J. Y., Gallez-hawkins, G., Thao, L., Oki, A., Lacey, S. F., Dagis, A., Palmer, J. M., Diamond, D., Forman, S., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.11.030 · Cited by 93
“However, the effect of KIR haplotypes on outcome remains controversial with beneficial and detrimental effects observed depending on whether it was a related sibling transplant [13] or unrelated transplant [8,25], whether it was T cell-depleted [10] or T cell repletetransplant [12], and other aspects such as myeloid d…”
Human Cytokine-Induced Memory-Like Natural Killer Cells
Berrien-Elliott, M. M., Wagner, J. A., & Fehniger, T. A. (2015) · Journal of Innate Immunity · doi:10.1159/000382019 · Cited by 111
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00262 · Cited by 101
Memory-like natural killer cells for cancer immunotherapy
Gang, M., Wong, P., Berrien-Elliott, M. M., & Fehniger, T. A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.11.003 · Cited by 105
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript ML NK cells are being testedas a therapy for AML relapse after HCT, used in concert with standard of care salvage chemotherapy followed by DLI (ClinicalTrials.gov, NCT03068819).”
BackgroundInfluentialOvercoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 101
“reported that host HLA-I-donor KIR mismatch can promote NK cell graftversus-leukemia effect (GvL) in transplant setting (“missingself”), therefore allogenic NK cells have been preferentially selected because exhibit additional advantages to being readyto-use product (27).”
BackgroundCAR-NK cell therapy: promise and challenges in solid tumors
Balkhi, S., Zuccolotto, G., Spirito, A. D., Rosato, A., & Mortara, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574742 · Cited by 109
Khaznadar, Z., Boissel, N., Agaugué, S., Henry, G., Cheok, M. H.-C., Vignon, M., Géromin, D., Cayuela, J., Castaigné, S., Pautas, C., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500262 · Cited by 101
“AML cells can trigger NK cell cytotoxicity and IFN-g release, as demonstrated in adoptive therapy approaches involving allogeneic NK cells (2, 4).”
BackgroundRajalingam, R., Du, Z., Meenagh, A., Luo, L., Kavitha, V. J., Pavithra-Arulvani, R., Vidhyalakshmi, A., Sharma, S. K., Balazs, I., Reed, E. F., et al. (2008) · Immunogenetics · doi:10.1007/s00251-008-0286-2 · Cited by 97
“NK cells further play a role in eliminating tumors (Cerwenka and Lanier 2001), rejecting allogeneic bone marrow transplants (Parham and McQueen 2003; Ruggeri et al. 2002 ) and promoting placental development (Hanna et al. 2006).”
BackgroundChang, Y., Zhao, X., Huo, M.-R., Xu, L., Liu, D., Liu, K., & Huang, X. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9630-7 · Cited by 94
“Haploidentical/mismatched transplantation allows for the use of hematopoietic stem cell transplant (HSCT) in nearly all patients who do not have a human leukocyte antigen (HLA) completely matched sibling or who require urgent transplantation [1–10].”
BackgroundTherapeutic applications: natural killer cells in the clinic
Miller, J. S. (2013) · Hematology · doi:10.1182/asheducation-2013.1.247 · Cited by 96
Muccio, L., Bertaina, A., Falco, M., Pende, D., Meazza, R., Lopez-Botet, M., Moretta, L., Locatelli, F., Moretta, A., & Chiesa, M. D. (2016) · Haematologica · doi:10.3324/haematol.2015.134155 · Cited by 94
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Isidori, A., Cerchione, C., Daver, N. G., Dinardo, C. D., Garcia‐Manero, G., Konopleva, M. Y., Jabbour, E. J., Ravandi, F., Kadia, T. M., Burguera, A. D. L. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656218 · Cited by 101
“Infusion of Haploidentical NK Cells NK cells have a major role in the eradication of residual AML cells after haploidentical SCT (108), boosting graft-versusleukemia (GVL) effects without exacerbating graft-versus-host disease (GVHD).”
BackgroundRomanski, A., Bug, G., Becker, S., Kampfmann, M., Seifried, E., Hoelzer, D. F., Ottmann, O. G., & Tonn, T. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.11.006 · Cited by 93
“attributed to graft-vs-leukemia activity of NK cells arising from the transplant [13].”
BackgroundInfluentialShaping of NK Cell Responses by the Tumor Microenvironment
Stojanovic, A., Correia, M. P., & Cerwenka, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0125-8 · Cited by 105
Bari, R., Granzin, M., Tsang, K. S., Roy, A., Krueger, W., Orentas, R., Schneider, D., Pfeifer, R., Moeker, N., Verhoeyen, E., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02001 · Cited by 90
“In T cell depleted HSCT, however, donor NK cells can facilitate engraftment, combat infection, and control cancer recurrence without causing GVHD (5, 6).”
BackgroundMarcenaro, E., Cantoni, C., Pesce, S., Prato, C., Pende, D., Agaugué, S., Moretta, L., & Moretta, A. (2009) · Blood · doi:10.1182/blood-2009-05-222265 · Cited by 97
Guo, M., Hu, K., Liu, G.-X., Yu, C., Qiao, J., Sun, Q., Qiao, J.-X., Dong, Z., Sun, W.-J., Sun, X., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0281 · Cited by 92
Wolschke, C., Stübig, T., Hegenbart, U., Schönland, S. O., Heinzelmann, M., Hildebrandt, Y., Ayuk, F. A., Atanackovic, D., Dreger, P., Zander, A. R., et al. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.10.004 · Cited by 94
Immune-based therapies for childhood cancer
Mackall, C. L., Merchant, M. S., & Fry, T. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.177 · Cited by 98
Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?
Chang, Y., & Huang, X. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.11.002 · Cited by 93
Memory-Like NK Cells: Remembering a Previous Activation by Cytokines and NK Cell Receptors
Pahl, J. H. W., Cerwenka, A., & Ni, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02796 · Cited by 101
Zhang, S., Liu, W., Hu, B., Wang, P., Lv, X., Chen, S., & Shao, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01242 · Cited by 111
“A higher incidence of tumor was observed in the population with low NK cell cytotoxic activity, which further suggested that NK cells played a vital role in tumor immunosurveillance (8, 9).”
BackgroundAversa, F. (2008) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705966 · Cited by 94
“Besides immediate donor availability, mismatched family donors offer several other advantages: (1) ability to select the best of many relatives on the basis of age, infectious disease status and natural killer (NK) cell alloreactivity”
BackgroundSelf-citationLundqvist, A., Yokoyama, H., Smith, A. L., Berg, M., & Childs, R. W. (2009) · Blood · doi:10.1182/blood-2008-11-190421 · Cited by 91
Natural killer cell alloreactivity in allogeneic hematopoietic transplantation
Ruggeri, L., Mancusi, A., Burchielli, E., Aversa, F., Martelli, M., & Velardi, A. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3280148a1a · Cited by 101
Self-citationBjörklund, A., Schaffer, M., Fauriat, C., Ringdén, O., Remberger, M., Hammarstedt, C., Barrett, A., Ljungman, P., Ljunggren, H., & Malmberg, K. (2010) · Blood · doi:10.1182/blood-2009-07-229740 · Cited by 93
“5-65) 40 (1-64) 42 (1-65) AML 46 (8-65) 40 (1-64) 41 (1-65) MDS 54 (2.”
Bethge, W. A., Haegele, M., Faul, C., Lang, P., Schumm, M., Bornhäuser, M., Handgretinger, R., & Kanz, L. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.08.009 · Cited by 91
Lundqvist, A., McCoy, J. P., Samsel, L., & Childs, R. W. (2006) · Blood · doi:10.1182/blood-2006-05-024315 · Cited by 97
Brehm, C., Huenecke, S., Quaiser, A., Esser, R., Bremm, M., Kloeß, S., Soerensen, J., Kreyenberg, H., Seidl, C., Becker, P. S. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027351 · Cited by 96
“In contrast, the predominance of inhibitory signals is mediated by killer immunoglobulin-like receptors (KIR) [6–8].”
BackgroundNatural killer cells in the treatment of high-risk acute leukaemia
Locatelli, F., Moretta, F., Brescia, L. P., & Merli, P. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.004 · Cited by 99
Lee, C. J., Savani, B. N., Mohty, M., Labopin, M., Ruggeri, A., Schmid, C., Baron, F., Esteve, J., Gorin, N. C., Giebel, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.176107 · Cited by 90
NK cell therapy for hematologic malignancies
Mehta, R., Randolph, B., Daher, M., & Rezvani, K. (2018) · International journal of hematology · doi:10.1007/s12185-018-2407-5 · Cited by 80
“[2] in a study of patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) who underwent T cell-depleted PB haploidentical transplant.”
Schaffer, M., Malmberg, K., Ringdén, O., Ljunggren, H., & Remberger, M. (2004) · Transplantation · doi:10.1097/01.tp.0000137103.19717.86 · Cited by 95
“GVHD prophylaxis CsA MTX (%) 87 (93) 59 (81) 18 (78) CsA prednisolone (%) 5 (5) 3 (4) 1 (4) CsA MMF (%) 2 (2) 4 (5) 0 TcD (%) 0 7 (10) 4 (17) ATG source Rabbit ATG 78 (83) 59 (81) 20 (87) OKT-3 15 (16) 14 (19) 3 (13) Campath 1 0 0 Follow-up (yr) 3.”
BackgroundInfluentialStringaris, K., Adams, S., Uribe, M. R., Eniafe, R., Wu, C. O., Savani, B., & Barrett, A. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.004 · Cited by 97
“The disease specificity of our finding, with the impact of KIR group genetics mainly affecting AML, is consistent with findings from other centers where NK-KIR-mediated effects have been found to be strongest in AML [10,11] as well as studies showing that alloreactive NK cells do not kill ALL cells in vitro [19].”
MethodResultLozupone, F., Pende, D., Burgio, V. L., Castelli, C., Spada, M., Venditti, M., Luciani, F., Lugini, L., Federici, C., Ramoni, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1501 · Cited by 91
de Lalla, C., Rinaldi, A., Montagna, D., Azzimonti, L., Bernardo, M. E., Sangalli, L. M., Paganoni, A. M., Maccario, R., Cesare‐Merlone, A. D., Zecca, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003748 · Cited by 90
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Kamiya, T., Chang, Y.-H., & Campana, D. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0229 · Cited by 95
Haploidentical transplantation for hematologic malignancies: where do we stand?
Fuchs, E. J. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.230.3798312 · Cited by 102
TLR Ligands Stimulation Protects MSC from NK Killing
Giuliani, M., Bennaceur-Griscelli, A., Nanbakhsh, A., Oudrhiri, N., Chouaib, S., Azzarone, B., Durrbach, A., & Lataillade, J.-J. (2014) · Stem Cells · doi:10.1002/stem.1563 · Cited by 91
Present and Future of Allogeneic Natural Killer Cell Therapy
Lim, O., Jung, M. Y., Hwang, Y. K., & Shin, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00286 · Cited by 97
“Several groups have explored the use of allogeneic NK cells in treating relapses of hematologic malignancies following HLA-haploidentical HSCT in clinical trials, and GVHD did not develop when allogeneic haploidentical NK cells were used (19, 24).”
BackgroundInfluentialThe BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
Salih, J., Hilpert, J., Placke, T., Grünebach, F., Steinle, A., Salih, H. R., & Krusch, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25233 · Cited by 98
Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
Giannattasio, A., Weil, S., Kloeß, S., Ansari, N., Stelzer, E. H. K., Cerwenka, A., Steinle, A., Koehl, U., & Koch, J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1321-y · Cited by 104
“Due to their natural ability to lyse tumor cells without prior sensitization, NK cells hold promise for cancer immunotherapy [4-8].”
Understanding and harnessing the graft‐versus‐leukaemia effect
Barrett, A. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07260.x · Cited by 89
“Activating receptors include NKG2D, and KIR groups with a short intracytoplasmic tail which do not transmit negative signals following the engagement of the KIR molecule with its cognate MHC class I molecule (Ruggeri et al, 2002).”
Backgroundγ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs
Gründer, C., van Dorp, S., Hol, S., Drent, E., Straetemans, T., Heijhuurs, S., Scholten, K., Scheper, W., Sebestyen, Z., Martens, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-432427 · Cited by 89
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg, K., Bryceson, Y. T., Carlsten, M., Andersson, S., Björklund, A. T., Björkström, N. K., Baumann, B. C., Fauriat, C., Alici, E., Dilber, M. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0492-7 · Cited by 98
“Since the initial report by Velardi and collaborators [101], numerous studies have addressed the role of KIR-ligand mis-match in diVerent settings of transplantation [34, 102].”
Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo, A. P., Sormani, M. P., Lamparelli, T., Gualandi, F., Occhini, D., Bregante, S., Raiola, A. M., Grazia, C. D., Dominietto, A., Tedone, E., et al. (2004) · PubMed · Cited by 89
Self-citationTerunuma, H., Deng, X., Dewan, M. Z., Fujimoto, S., & Yamamoto, N. (2008) · International Reviews of Immunology · doi:10.1080/08830180801911743 · Cited by 93
“of KIR-incompatible, T-cell-depleted alloreactive donor NK cells [55].”
The Pathophysiology of Graft‐Vs.‐Host Disease
Ferrara, J. L. M., & Antin, J. H. (2003) · Wiley eBooks · doi:10.1002/9780470987070.ch27 · Cited by 93
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.